[1]Pennings MT， Derksen RH， van Lummel M， et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′[J]. J Thromb Haemost， 2007， 5(2): 369-377. [2]Urbanus RT， Siegerink B， Roest M， et al. Anti-phospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study[J]. Lancet Neurol， 2009， 8(11): 998-1005. [3]Van Lummel M， Pennings MT， Derksen RH， et al. The binding site in {beta}2- glycoprotein I for ApoER2′ on platelets is located in domain V[J]. J Biol Chem， 2005， 280(44): 36729-36736.[4] Agar C， van Os GM， Mrgelin M， et al. Beta2-glycoprotein I can exist in 2 conformations:implications for our understanding of the antiphospholipid syndrome[J]. Blood， 2010，116(8):1336-1343.[5]Ioannou Y， Zhang JY， Passam FH， et al. Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation， redox modification by endothelial cells， and regulation of oxidative stress-induced cell injury[J]. Blood， 2010， 116(11): 1961-1970.[6]Passam FH ， Giannakopoulos B ， Miarabshahi P ， et al. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I[J]. J Thromb Haemost， 2011， 9(Suppl1) : 275-282.[7]Rahgozar S， Giannakopoulos B， Yan X ， et al. Beta 2-glycoprotein Ⅰ protects thrombin from inhibition by heparin cofactor Ⅱ: potentiation of this effect in the presence of anti-beta2-glycoprotein Ⅰ autoantibodies[J]. Arthritis Rheum， 2008， 58(4): 1146-1155.[8]Kuwana M， Matsuura E， Kobayashi K， et al. Bind-ing of 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells[J]. Blood， 2005，105(4):1552-1557.[9] De Laat BD， Derksen RH， Lummel MV， et al. Patho-genic anti-beta2-glycoprotein I antibodies recognize domain I of beta-glycoprotein I only after a conforma-tional change[J]. Blood， 2006，107(5):1916-1924.[10]Rand JH . A new fish for the β2GPⅠ hook: LPS[J]. Blood ， 2011，117(25):6743-6744.[11]White-Adams TC， Berny MA， Tucker EI，et al . Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2)[J]. Arterioscler Thromb Vasc Biol， 2009， 29(10): 1602-1607.[12]Romay-Penabad Z， Aguilar-Valenzuela R， Urbanus RT， et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome[J]. Blood， 2011，117(4):1408-1414.[13]Urbanus RT ， Pennings MT ， Derksen RH， et al. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′[J]. J Thromb Haemost， 2008， 6(8): 1405-1412.[14]White TC， Berny MA， Tucker EI， et al . Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2′[J]. J Thromb Haemost， 2008， 6(6): 995-1002.[15] Stolt PC， Bock HH. Modulation of lipoprotein receptor functions by intracellular adaptor proteins[J]. Cell Signal ， 2006，18(10):1560-1571.[16]Pennings MT， van Lummel MV ， Derksen RH ， et al. Interaction of beta2 -glycoprotein I with members of the low density lipoprotein receptor family[J]. J Thromb Haemost， 2006， 4(8): 1680-1690.[17]Sikara MP， Routsias JG， Samiotaki M， et al. {beta}2 glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of anti-phospholipid syndrome[J]. Blood， 2010，115(3):713-723.[18]Hulstein JJ， de Lenting PJ， de Laat BD， et al.Beta2-glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation[J]. Blood，2007，110(5):1483-1491．[19]Passam FH ， Rahgozar S， Qi M ，et al. Redox control of beta2-glycoprotein I-von Willebrand factor inter-action by thioredoxin-1[J]. J Thromb Haemost， 2010，8(8): 1754-1762.[20]Vega-Ostertag ME， Ferrara DE， Romay-Penabad Z， et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation[J]. J Thromb Haemost， 2007， 5(9):1828-1834.[21]Montiel-Manzano G， Romay-Penabad Z， Papalardo de Martinez E， et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies[J]. Ann N Y Acad Sci， 2007，1108:540-553.
